Astellas (4503) - PROSPER Data Revives Value Story
For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of...
150 Views
Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
153 Views
The Week That Was in NorthAsia@Smartkarma: NK Nuke, Topix, Nikkei 225, & HHI Recapitalization
Below is the full list of Japan/Korea related reports published last week on Smartkarma.TOPIX inclusion eventTravis touched on the stocks to be...
193 Views
Did AstraZeneca Really Bid for Daiichi Sankyo, Did Daiichi Sankyo Really Turn Them Down?
A story run by Nikkei Business that AstraZeneca (AZN LN) offered to buy Daiichi Sankyo (DSK) last year provided a frisson of excitement in the...
159 Views
1Q Results a Good Start in Japan - 133 Names Achieved More than 30% of Full-Year OP Guidance....
With approx. 90% of names with mkt-cap above ¥50bn already announcing 1Q results, we looked back to see how companies did. If we look at the...
394 Views